

first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

12. (Amended) An isolated nucleic acid encoding a peptide according to claim 1.

13. (Amended) An antibody or binding fragment capable of selectively binding to a peptide according to claim 1.

17. (Amended) The method according to claim 15 further comprising the step of testing the ability of the modulator to modulate at least one of fibrin fragment E induced cell proliferation and/or angiogenesis.

18. (Amended) A process for producing a modulator comprising the step of identifying the modulator according to the method of claim 15.

19. (Amended) A modulator of fibrin fragment E activity identified by the method according to claim 15.

21. (Amended) A composition comprising a peptide according to claim 1 in association with a pharmaceutically acceptable carrier or diluent.

22. (Amended) A coronary stent comprising a peptide according to claim 1.

23. (Amended) A method of inhibiting stimulation of cell proliferation induced by fibrin fragment E comprising bringing the cell into contact with a peptide according to claim 1.

29. (Amended) A nucleic acid primer consisting essentially of a sequence of between about 15 to 50 nucleotides encoding a peptide according to claim 1.

Add new claims 30-37 as follows:

---

30. A variant peptide which is a variant of a fragment according to claim 6, which variant has one amino acid substitution, insertion or deletion with respect to said fragment wherein the variant peptide is capable of modulating a fibrin fragment E activity.

31. A fragment of a peptide according to claim 4 wherein said activity is stimulation of cell proliferation or angiogenesis.

32. A fusion peptide which comprises a first portion having the amino acid sequence of a fragment of a peptide according to claim 4 and a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion, said second portion comprising a membrane translocation sequence.

33. An isolated nucleic acid encoding a fragment of a peptide according to claim 4.

34. An antibody or binding fragment capable of selectively binding to a fragment of a peptide according to claim 4.

35. An antibody according to claim 34 which is a monoclonal antibody, a polyclonal antibody or antiserum.

36. A composition comprising a fragment of a peptide according to claim 4 in association with a pharmaceutically acceptable carrier or diluent.

37. A coronary stent comprising a fragment of a peptide according to claim 4.

---

Please cancel claims 20, 25 and 26.